Abstract
To the Editor: Olivieri et al. (April 6 issue)1 are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.2–5 Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.2 We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies.
Original language | English (US) |
---|---|
Pages (from-to) | 597-599 |
Number of pages | 3 |
Journal | New England Journal of Medicine |
Volume | 333 |
Issue number | 9 |
DOIs | |
State | Published - Aug 31 1995 |
ASJC Scopus subject areas
- General Medicine